Page last updated: 2024-11-06

n-diazoacetylnorleucine methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-diazoacetylnorleucine methyl ester: a pepsin inhibitor; RN given refers to (DL)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-diazoacetylnorleucine methyl ester : A diazonium betaine obtained by the deprotonation of the hydroxy group of (Z)-2-hydroxy-2-{[(2S)-1-methoxy-1-oxohexan-2-yl]amino}ethenediazonium. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7408226
CHEBI ID74350
SCHEMBL ID1508067
MeSH IDM0040887

Synonyms (7)

Synonym
n-diazoacetylnorleucine methyl ester
(z)-2-diazonio-1-{[(2s)-1-methoxy-1-oxohexan-2-yl]amino}ethenolate
CHEBI:74350
SCHEMBL1508067
methyl (2s)-2-[(2-diazoacetyl)amino]hexanoate
diazoacetyl-norleucine methyl ester
Q27144629
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's5 (35.71)18.2507
2000's5 (35.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]